Nicola Dalbeth is a Specialist Rheumatologist and Professor of Medicine from Auckland, New Zealand. She leads a research programme focusing on the mechanisms, impact and treatment of gout. She has been principal investigator on international phase 3 clinical trials of novel therapeutic agents for gout, and has led international initiatives to define central concepts of gout, including nomenclature of disease, outcome measures in clinical trials, and response to treatment. She served as a member of the core oversight team for the American College of Rheumatology (ACR) Gout Management Guidelines, and as a steering committee on the 2015 ACR/European League Against Rheumatism gout classification project.
Research & Clinical Focus
[International Symposium] Gout : Comorbidity Matters and Optimal Management Strategies